C4 Therapeutics Inc (CCCC) - News Archive

In an era where multiple myeloma therapies are rapidly evolving, C4 Therapeutics Inc. has emerged front and center with their promising investigational drug, Cemsidomide. Presented at the International Myeloma Society A...

C4 Therapeutics, a biopharmaceutical company specializing in the development of targeted protein degradation therapies, recently announced the dosing of the first patient in a clinical trial for its investigational drug...

Advancements in Cancer Treatment: C4 Therapeutics to Unveil Promising Data on Cemsidomide at ASH Annual Meeting The Stage is Set In the rapidly evolving landscape of cancer treatment, C4 Therapeutics (C4T) is poised to...

Delivery of Second Development Candidate to Biogen Marks Key MilestoneWATERTOWN, Mass. November 28, 2023 C4 Therapeutics, Inc. (C4T), a cutting-edge biopharmaceutical company at the forefront of targeted protein degrada...

News C4 Therapeutics, a leader in the development of targeted protein degradation therapies, has announced its plans to present preliminary clinical data from the Phase 1 monotherapy trial of CFT1946 at the upcoming Eur...

In this week s market performance, C4 Therapeutics Inc shares have been trailing behind the overall market. However, recent developments and positive signs suggest that the stock may have further upside potential.Last s...

Innovating Oncology: C4 Therapeutics to Reveal Pioneering Data on Targeted Protein Degradation at ESMO Congress 2024 July 16, 2024 | Watertown, Mass. C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a trailblazing clinical-s...

C4 Therapeutics Announces Inducement Grant and Potential Impact on Company SharesWATERTOWN, Mass., April 29, 2024 - C4 Therapeutics, a clinical-stage biopharmaceutical company focused on targeted protein degradation sci...

C4 Therapeutics Makes a Splash with Groundbreaking Preclinical Data on BiDAC DegradersAt the American Association for Cancer Research Annual Meeting 2024, C4 Therapeutics unveiled exciting new preclinical data showcasin...

In a significant development that highlights the increasing importance of targeted protein degradation in oncology research, C4 Therapeutics (C4T) has announced a strategic discovery research collaboration with Merck KG...

C4 Therapeutics, a frontrunner in the biopharmaceutical landscape, has recently revealed its strategic plan for 2024, outlining a keen focus on the development and progression of targeted protein degradation (TPD) medic...

WATERTOWN, Mass., Jan. 04, 2024 - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, has successfully finalized a significant milestone in its mission to revolutionize disease treatm...

:In a significant step forward for the field of oncology research, C4 Therapeutics has recently announced a strategic license and research collaboration with Merck. The partnership aims to explore the development of Deg...

C4 Therapeutics, Inc. (C4T), a clinical-stage biopharmaceutical company pioneering targeted protein degradation science, recently announced the presentation of new Phase 1 dose escalation data for relapsed/refractory mu...